Related Experiment Video
Updated: Mar 27, 2026
09:39
Assessing Specificity of Anticancer Drugs In Vitro
Published on: March 23, 2016
9.9K
Outcomes of Patients Treated With Dasatinib 50 mg/d: A Pooled Analysis
Fadi G Haddad1, Elias Jabbour1, Koji Sasaki1
1MD Anderson Cancer Center, Department of Leukemia, The University of Texas, Houston, TX.
Clinical Lymphoma, Myeloma & Leukemia
|March 24, 2026
Summary
Frontline dasatinib 50 mg/d demonstrates high efficacy in newly diagnosed chronic myeloid leukemia (CML-CP) patients. Long-term follow-up confirms excellent molecular response rates, event-free survival, and overall survival with manageable safety.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Dasatinib is approved for chronic myeloid leukemia in chronic phase (CML-CP) at 100 mg/d.
- This study investigates outcomes using a lower frontline dose of dasatinib (50 mg/d).
Purpose of the Study:
- To evaluate the efficacy and safety of frontline dasatinib 50 mg/d in patients with newly diagnosed CML-CP.
- To assess molecular response rates, event-free survival (EFS), and overall survival (OS) in this cohort.
Main Methods:
- A phase II clinical trial included 149 patients with newly diagnosed CML-CP.
- Patients received either dasatinib 50 mg/d alone or in combination with venetoclax.
- Molecular responses, adverse events, EFS, and OS were evaluated.
Main Results:
- At 60 months, cumulative rates for major molecular response, MR4, and MR4.5 were 95%, 87%, and 86%, respectively.
- Five-year EFS and OS rates were 96% and 98%, respectively, with a median follow-up of 73 months.
- 48% of patients experienced adverse events, with Grade 3 pleural effusion in 2%.
Conclusions:
- Frontline dasatinib 50 mg/d is safe and effective for newly diagnosed CML-CP.
- Long-term follow-up supports the use of this lower dose regimen.
